Antiviral Therapy

Papers
(The TQCC of Antiviral Therapy is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients22
RVX-208, an inducer of Apolipoprotein A-I, inhibits the particle production of hepatitis B virus through activation of cGAS-STING pathway22
Inhibition of chikungunya virus replication by N-ω-Chloroacetyl-L-Ornithine in C6/36, Vero cells and human fibroblast BJ14
Understanding the effect of direct-acting antiviral therapy on weight in patients with chronic hepatitis C12
Real-life findings on the impact of the COVID-19 pandemic on HIV care12
Preface: Special Collection Commemorating John C. Martin12
Commentary: Development of Therapeutics for Congenital Cytomegalovirus Infection11
Evaluation of doravirine-based regimen population target in a large Italian clinical center11
Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives10
Case study of hepatitis C virus control in Egypt: impact of access program10
Tenofovir alafenamide fumarate9
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B9
Providing access to high-quality, low-cost medicines across low and middle-income countries (LMICs), working with governments and generic manufacturers around the globe - A business case8
Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-198
Feminizing hormone therapy in a Canadian cohort of transgender women with and without HIV7
HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective7
Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study6
Nirmatrelvir treatment duration and frequency of COVID-19 rebound6
Progress in the quality of care for newly diagnosed people with HIV in Spain (2004–2019)6
Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically-suppressed patients: real world data from a monocentric cohort6
Dolutegravir and rilpivirine as successful initial antiretroviral therapy in a treatment-naive patient with HIV-1: A case report5
Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting4
Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial4
Adefovir for lamivudine-resistant hepatitis B4
Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)–infected patients4
A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults4
The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir4
The making of the one pill—Developing single tablet regimens for HIV and for HCV4
A Phase 1 randomized study of GSK3732394, an investigational long-acting biologic treatment regimen for HIV-1 infection4
Preemptive acyclovir to prevent herpes simplex virus bronchopneumonitis in mechanically ventilated patients with herpes simplex virus oropharyngeal reactivation: An ancillary study of the preemptive t4
Socioeconomic status largely explains integrase inhibitors-related body composition differences in chronically infected men living with HIV4
Antiretroviral therapy achieved metabolic complete remission of hepatic AIDS related Epstein-Barr virus-associated smooth muscle tumor4
0.13463306427002